open access

Vol 11, No 4 (2015)
Guidelines / Expert consensus
Published online: 2015-08-27
Get Citation

Recommendations on the application of positron emission tomography in oncology

Maciej Krzakowski, Piotr Rutkowski, Jacek Jassem, Renata Zaucha, Jacek Fijuth, Janusz Słuszniak, Barbara Jarząb, Wojciech Zegarski, Bogdan Małkowski, Andrzej Kawecki, Witold Rzyman, Andrea D’Amico, Andrzej Stelmach, Wojciech Polkowski, Radosław Mądry, Leszek Królicki
Oncol Clin Pract 2015;11(4):155-172.

open access

Vol 11, No 4 (2015)
EXPERTS' OPINION
Published online: 2015-08-27

Abstract

Positron emission tomography (PET) is a modern functional imaging method with proven value in diagnosing, staging, evaluating of response to anticancer therapy and detecting of relapses in numerous neoplasms. Utility, sensitivity and specificity of PET has increased by its use in combination with computed tomography (CT) or magnetic resonance in form of fusion PET-CT or PET-MR and the introduction of new radiotracers. This paper, prepared based on scientific evidence by a multidisciplinary group of authors, presents the utility and clinical recommendations for the application of PET-CT in oncology. PET-CT is particularly useful for:

— appropriate diagnosis and initial staging of patients with head and neck, lung, pancreatic and esophageal cancers as well as lymphomas, advanced melanomas and tumors of unknown primary site;

— detection of relapses inpatients with colorectal, thyroid, ovarian, head and neck, and breast cancers, as well as lymphomas;

— monitoring of response to therapy in patients with testicular and lung cancers, lymphomas and some types of sarcomas. PET-MR is particulary useful in pediatrics.  

Abstract

Positron emission tomography (PET) is a modern functional imaging method with proven value in diagnosing, staging, evaluating of response to anticancer therapy and detecting of relapses in numerous neoplasms. Utility, sensitivity and specificity of PET has increased by its use in combination with computed tomography (CT) or magnetic resonance in form of fusion PET-CT or PET-MR and the introduction of new radiotracers. This paper, prepared based on scientific evidence by a multidisciplinary group of authors, presents the utility and clinical recommendations for the application of PET-CT in oncology. PET-CT is particularly useful for:

— appropriate diagnosis and initial staging of patients with head and neck, lung, pancreatic and esophageal cancers as well as lymphomas, advanced melanomas and tumors of unknown primary site;

— detection of relapses inpatients with colorectal, thyroid, ovarian, head and neck, and breast cancers, as well as lymphomas;

— monitoring of response to therapy in patients with testicular and lung cancers, lymphomas and some types of sarcomas. PET-MR is particulary useful in pediatrics.  

Get Citation

Keywords

positron emission tomography, oncology, diagnosis, staging, response to treatment, recommendations

About this article
Title

Recommendations on the application of positron emission tomography in oncology

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 4 (2015)

Article type

Guidelines / Expert consensus

Pages

155-172

Published online

2015-08-27

Bibliographic record

Oncol Clin Pract 2015;11(4):155-172.

Keywords

positron emission tomography
oncology
diagnosis
staging
response to treatment
recommendations

Authors

Maciej Krzakowski
Piotr Rutkowski
Jacek Jassem
Renata Zaucha
Jacek Fijuth
Janusz Słuszniak
Barbara Jarząb
Wojciech Zegarski
Bogdan Małkowski
Andrzej Kawecki
Witold Rzyman
Andrea D’Amico
Andrzej Stelmach
Wojciech Polkowski
Radosław Mądry
Leszek Królicki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl